ORCHESTRA BIOMED HOLDINGS, INC.

Other languages Orchestra BioMed Holdings, Inc.

Equities

OBIO

US68572M1062

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-24 EDT			5-day change	1st Jan Change
5.3 ^USD	+1.53%		+1.73%	-41.95%

05-13	Earnings Flash (OBIO) ORCHESTRA BIOMED HOLDINGS Reports Q1 Revenue $620,000	MT
05-13	Orchestra BioMed Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Orchestra BioMed Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13
Orchestra BioMed Holdings, Inc. Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents	04-30
Orchestra BioMed Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-27
Orchestra BioMed Holdings, Inc. Announces Appointment of David Pacitti to Board of Directors	03-26
Orchestra Biomed Holdings, Inc. Demonstrates Strength of Cardiovascular Pipeline with Virtue SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting	03-13
Orchestra Biomed Holdings, Inc. Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy in Hypertensive Pacemaker Patients	03-06
Orchestra Biomed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with Avim Therapy for over 3 Years	02-26
Orchestra Biomed Announces Initiation of Backbeat Pivotal Study of Avim Therapy in Hypertensive Pacemaker Patients	01-08
Sector Update: Health Care Stocks Steady Late Afternoon	23-09-19
Sector Update: Health Care Stocks Lower Tuesday Afternoon	23-09-19
Sector Update: Health Care	23-09-19
Orchestra BioMed Gets FDA Approval to Begin Study of BackBeat CNT for Hypertension in Pacemaker Patients; Shares Jump	23-09-19
Orchestra Biomed Holdings, Inc. Receives Fda Approval of Ide for U.S. Pivotal Study of Virtue(R) Sirolimus Angioinfusion Balloon in Patients with Coronary In-Stent Restenosis	23-08-08
Orchestra BioMed Names Andrew Taylor as Finance Chief	23-06-07
Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy	23-06-07
Orchestra BioMed Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12
Orchestra BioMed Holdings, Inc. Announces Management Changes	23-02-07
Top Premarket Decliners	23-01-30
Orchestra BioMed, Inc. completed the acquisition of Health Sciences Acquisitions Corporation 2 from HSAC 2 Holdings, LLC, RTW Investments, LP and others in a reverse merger transaction.	23-01-25

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer